Basal metabolic rate and Charlson Comorbidity Index are independent predictors of metabolic syndrome in patients with rheumatoid arthritis - 26/09/20
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 6 |
| Iconografia | 1 |
| Video | 0 |
| Altro | 0 |
Highlights |
• | Patients with rheumatoid arthritis had a higher annual incidence rate (11.5%) of metabolic syndrome, compared to the general population. |
• | Lower basal metabolic rate and higher Charlson Comorbidity Index scores were significant predictors for development of metabolic syndrome in patients with rheumatoid arthritis. |
Abstract |
Objective |
To prospectively analyze predictors of metabolic syndrome (MetS) in patients with rheumatoid arthritis (RA) during 2years of follow-up.
Methods |
We recruited 319 consecutive patients with RA who did not have MetS. MetS was defined in accordance with the modified National Cholesterol Education Program/Adult Treatment Panel III 2005 for Asian populations. Sociodemographic data, laboratory findings, disease activity data, and medication history were collected during face-to-face interviews at baseline and follow-up. Independent predictors of MetS were assessed by univariate and multivariate logistic regression analyses.
Results |
Of the 247 patients with RA who completed the 2-year follow-up, 37 (15.0%) developed MetS. At baseline, these patients were older and had higher body mass index, waist circumference, waist-hip ratio, skeletal muscle mass, body fat mass, percent body fat, and Charlson Comorbidity Index scores, as well as lower basal metabolic rate (BMR). Moreover, these patients with MetS took less hydroxychloroquine and more oral hypoglycemic agents; they also had lower European Quality of Life Health-state Questionnaire scores. After exclusion of variables associated with MetS composition, multivariate analysis identified BMR (odds ratio [OR]=0.205, 95% confidence interval [CI]: 0.078–0.541, P=0.001) and Charlson Comorbidity Index score (OR=2.191, 95% CI: 1.280–3.751, P=0.004) as significant predictors of MetS.
Conclusions |
Our study showed that the annual incidence rate of MetS was 11.5% in patients with RA. Moreover, the development of MetS was associated with BMR and Charlson Comorbidity Index score at baseline.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Rheumatoid arthritis, Metabolic syndrome, Basal metabolic rate, Comorbidity
Mappa
Vol 87 - N° 5
P. 455-460 - ottobre 2020 Ritorno al numero
Articolo precedente
- Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries
- Penélope Esther Palominos, Laura Coates, Charles Lubianca Kohem, Ana-Maria Orbai, Josef Smolen, Maarten de Wit, Uta Kiltz, Ying-Ying Leung, Juan D. Cañete, Rossana Scrivo, Andra Balanescu, Emmanuelle Dernis, Sandra Meisalu, Martin Soubrier, Sibel Zehra Aydin, Inna Gaydukova, Umut Kalyoncu, Laure Gossec
- Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial
- Ruixia Sun, Jie Lu, Hui Li, Xiaoyu Cheng, Ying Xin, Changgui Li
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?